Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating, Cuts Target Price to $15
Truist Financial Sticks to Their Buy Rating for Sutro Biopharma (STRO)
Express News | Sutro Biopharma Inc : Truist Securities Cuts Target Price to $15 From $18
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $8 to $17
Sutro Biopharma's Strong Financials and Clinical Progress Reinforce Buy Rating
Express News | Sutro Biopharma Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. Additionally, HC Wainwright Reiterated a Buy Rating on the Stock
Sutro Biopharma GAAP EPS of -$0.59, Revenue of $25.7M
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $5 to $12
Wedbush Sticks to Its Buy Rating for Sutro Biopharma (STRO)
Express News | HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Sutro Biopharma Analyst Ratings
Buy Rating Affirmed for Sutro Biopharma on Promising Luvelta and Bevacizumab Combination Therapy
Sutro Biopharma: A Stable Hold Amidst Anticipated Trial Updates and Market Perceptions
TD Cowen Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Sutro Biopharma | 10-Q: Q2 2024 Earnings Report
Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q2 Revenue $25.7M
Sutro Biopharma 2Q Loss $48M >STRO
Sutro Biopharma 2Q Loss/Shr 59c >STRO
Express News | Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Express News | Sutro Biopharma Q2 Operating Expenses USD 74.391 Million